Table 5 Cost-effectiveness analysis results according to PFS and OS for each treatment group. Amounts are presented in MXN pesos
TKI | Mean total cost | Incremental Cost | Effectiveness | Incremental Effectiveness | ICER |
|---|---|---|---|---|---|
Progression Free Survival (PFS) | |||||
Gefitinib | $161,800 | 8.18 | Lowest cost | ||
Erlotinib | $215,700 | $53,900 | 6.7 | −1.48 | Dominated by gefitinib |
Afatinib | $348,200 | $186,400 | 9.46 | 1.28 | $145,625.00 vs gefitinib |
Overall Survival (OS) | |||||
Gefitinib | $161,800 | 27.1 | Lowest cost | ||
Erlotinib | $215,700 | $53,900 | 21.7 | −5.4 | Dominated by gefitinib |
Afatinib | $348,200 | $186,400 | 37.1 | 10 | $18,640.00 vs gefitinib |